Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Accumulated Expenses (2020 - 2022)

Historic Accumulated Expenses for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $13.8 million.

  • Atea Pharmaceuticals' Accumulated Expenses fell 7104.78% to $13.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $13.8 million, marking a year-over-year decrease of 7104.78%. This contributed to the annual value of $52.2 million for FY2021, which is 26297.33% up from last year.
  • As of Q3 2022, Atea Pharmaceuticals' Accumulated Expenses stood at $13.8 million, which was down 7104.78% from $10.5 million recorded in Q2 2022.
  • In the past 5 years, Atea Pharmaceuticals' Accumulated Expenses registered a high of $52.2 million during Q4 2021, and its lowest value of $6.3 million during Q3 2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $15.1 million (2021), whereas its average is $24.7 million.
  • In the last 5 years, Atea Pharmaceuticals' Accumulated Expenses skyrocketed by 65208.2% in 2021 and then tumbled by 7236.11% in 2022.
  • Quarter analysis of 3 years shows Atea Pharmaceuticals' Accumulated Expenses stood at $14.4 million in 2020, then surged by 262.97% to $52.2 million in 2021, then tumbled by 73.53% to $13.8 million in 2022.
  • Its Accumulated Expenses stands at $13.8 million for Q3 2022, versus $10.5 million for Q2 2022 and $24.8 million for Q1 2022.